Condition
Lymphoma Neoplasms
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07609576RecruitingPrimary
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
NCT03338881Phase 1Withdrawn
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Showing all 2 trials